

FEATURE REVIEW

Autism as a disorder of neural information processing: directions for research and targets for therapy¹

MK Belmonte¹, EH Cook Jr², GM Anderson³, JLR Rubenstein⁴, WT Greenough⁵, A Beckel-Mitchener⁵, E Courchesne⁶, LM Boulanger⁷, SB Powell⁸, PR Levitt⁹, EK Perry¹⁰, YH Jiang¹¹, TM DeLorey¹² and E Tierney¹³

¹Autism Research Centre, Departments of Psychiatry and Experimental Psychology, University of Cambridge, UK;

²Departments of Psychiatry, Pediatrics, and Human Genetics, University of Chicago, Chicago, IL, USA; ³Child Study Center, Yale University, New Haven, CT, USA; ⁴Department of Psychiatry, University of California San Francisco, San Francisco, California, USA; ⁵Beckman Institute, University of Illinois, Urbana-Champaign, IL, USA; ⁶Department of Neurosciences, University of California San Diego, La Jolla, CA, USA; ⁷Department of Neurobiology, Harvard Medical School, Boston, MA, USA; ⁸Department of Psychiatry, University of California San Diego, San Diego, CA, USA; ⁹Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, TN, USA; ¹⁰Centre Development in Clinical Brain Ageing, University of Newcastle, Newcastle, UK; ¹¹Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA;

¹²Molecular Research Institute, Mountain View, CA, USA; ¹³Kennedy Krieger Institute, Baltimore, MD, USA

The broad variation in phenotypes and severities within autism spectrum disorders suggests the involvement of multiple predisposing factors, interacting in complex ways with normal developmental courses and gradients. Identification of these factors, and the common developmental path into which they feed, is hampered by the large degrees of convergence from causal factors to altered brain development, and divergence from abnormal brain development into altered cognition and behaviour. Genetic, neurochemical, neuroimaging, and behavioural findings on autism, as well as studies of normal development and of genetic syndromes that share symptoms with autism, offer hypotheses as to the nature of causal factors and their possible effects on the structure and dynamics of neural systems. Such alterations in neural properties may in turn perturb activity-dependent development, giving rise to a complex behavioural syndrome many steps removed from the root causes. Animal models based on genetic, neurochemical, neurophysiological, and behavioural manipulations offer the possibility of exploring these developmental processes in detail, as do human studies addressing endophenotypes beyond the diagnosis itself.

Molecular Psychiatry (2004) 9, 646–663. doi:10.1038/sj.mp.4001499

Published online 23 March 2004

Keywords: autism; development; neurochemistry; genetics; animal models

Autism and abnormal neural dynamics

Cognitively, autism has been construed as a disorder involving fundamental deficits in central coherence,¹ executive function,² and theory of mind³ or empathising.⁴ Anatomically, abnormalities have been localised in cerebellum and brain stem,⁵ hippocampus and amygdala,⁶ and frontal lobes^{7–9} and other neocortical

structures. These descriptions and findings are neither mutually exclusive nor mutually independent, and a complete explanation will encompass all of them. Arriving at such a unified explanation will depend on looking beyond developmental end points and surface diagnostic features, beyond the leaves of the developmental tree to its trunk and roots.

Autism is a developmental disorder not simply in terms of taxonomy but in terms of its detailed aetiology. It cannot be understood as if it were a lesion within an otherwise normal, fully developed brain, but must instead be approached as an emergent property of developmental interactions between many brain regions and functions.¹⁰ Primary dysfunctions can be masked by the evolution of compensatory processing strategies which normalise behaviour,¹¹ and also by the induction of activity-dependent secondary dysfunctions^{12,13} that disrupt behaviour in new ways. There is thus a high degree of fan-out (divergence) from core dysfunctions in the developing brain to cognitive and behavioural symptoms

¹This paper is the report of the meeting 'Pinpointing Autism: Neurochemical Targets and Research Directions in Developmental Neurobiology' convened by Cure Autism Now in Santa Monica, CA, April 2002. In addition to those workshop participants who have directly contributed to this review, we acknowledge the participation of Michael Merzenich, Eric Hollander, Steven Watkins, Maja Bucan, and Mark Geyer, whose insights have helped shape this discussion.

Correspondence: MK Belmonte, Autism Research Centre, Developmental Psychiatry, Douglas House, 18b Trumpington Road, Cambridge CB2 2AH, UK. E-mail: belmonte@mit.edu

Received 06 June 2003; revised 20 October 2003; accepted 04 February 2004

reflected in the developing child. The sheer number of genetic susceptibility factors and loci that have been linked to autism implies that autism admits a high degree of fan-in (convergence) from primary biasing factors to core dysfunctions. The 60% concordance for strictly diagnosed autism in identical twins¹⁴ establishes a role for environmental interactions in this fan-in just as surely as it does for genetic predispositions.

The very breadth of autism's anatomical and functional abnormalities admits the possibility that its core dysfunctions may involve some pervasive alteration of neural processing. One route to such an alteration might be via abnormally low signal-to-noise in developing neural assemblies, a condition that may be produced by abnormal neural connectivity. The high incidence of epilepsy in autism¹⁵ is consistent with this hypothesis, and there has been no shortage of relevant neuropathological findings. The numbers of Purkinje cells, and to a lesser extent granule cells, in cerebellar cortex are abnormally low¹⁶—presumably leading to disinhibition of the cerebellar deep nuclei and consequent overexcitation of thalamus and cerebral cortex. Neurons in hippocampus, amygdala, and other limbic regions are abnormally densely packed,^{16,17} and a Golgi analysis of the hippocampus in two autistic brains¹⁷ has revealed an abnormally low degree of dendritic branching. A recent photographic examination of neurons in several cortical regions suggests a reduction in the size of cortical minicolumns in the autistic brain, and an increase in cell dispersion within minicolumns—characteristics that could increase the total number of minicolumns and thus the degree of connectivity between minicolumns.¹⁸ It is important to note that a decrease in signal-to-noise can arise from abnormalities of connectivity in either direction: whereas an overconnected network passes so much noise that it swamps the signal, an underconnected network passes so little signal that it becomes lost in the noise. In either case, large segments of the network are constrained to either an all-on or an all-off state, and the network's information capacity is thereby reduced.¹⁹

Neurophysiologic and neuroanatomic effects

Neurophysiological consequences

Such a failure to delimit activation within an abnormally connected network may be observable as hyperarousal in response to sensory input, and decreased ability to select among competing sensory inputs.²⁰ Cardiovascular, neuroendocrine and neurochemical indices of arousal in novel and stressful situations are consistent with this prediction,^{21,22} as are physiological and behavioural observations of the extent and intensity of perceptual processing. Physiologically, functional imaging has demonstrated heightened activity in autism in brain regions associated with stimulus-driven, sensory processing, and decreased activity in regions that normally subservise higher-order processing: these results include abnor-

mally high activity in ventral occipital visual areas during a visual task even while prefrontal and parietal activations are abnormally low;²³ heightened activity during face processing in peristriate cortex,²⁴ inferior temporal gyrus,²⁵ and other areas outside the fusiform 'face area',²⁶ while fusiform activity is abnormally low; heightened activity in superior temporal gyrus during inference of mental state from pictures of eyes, while prefrontal and medial temporal activations are abnormally low;²⁷ and decreased connectivity between extrastriate visual areas and prefrontal and temporal areas associated with inference of mental state, while prefrontal and temporal activations are again abnormally low.²⁸

Supporting the idea of impaired selection of perceptual inputs, evoked potential and quantitative EEG studies reveal a pattern of abnormally distributed response in autism during tasks that demand selective attention. In adults with autism, the P1 evoked potential is either abnormally augmented in response to stimuli at the attended location, or abnormally generalised to stimuli distant from the attended location.²⁹ During shifts of attention between hemifields, the normal, spatiotopically selective augmentation of the visual steady-state evoked potential is absent, and instead both hemispheres activate indiscriminately during shifts of attention into either hemifield.^{30,20} In children with autism, the visual N2 to novel stimuli is augmented during task performance even when these stimuli are not relevant to the task.³¹ When a response is required to an auditory stimulus, the P3 in these same children is abnormally generalised to occipital sites overlying visual processing areas.³² In general, both in children and in adults, physiological measures (Figure 1) suggest that perceptual filtering in autism occurs in an all-or-none manner, with little specificity in selecting for the location of the stimulus, for the behavioural relevance of the stimulus, or even for the sensory modality in which the stimulus appears.

Recent fMRI evidence suggests that the autistic brain may compensate for this deficit in selecting sensory inputs by suppressing any irrelevant sensory information at a later, less efficient stage of processing.²⁰ In other words, in the absence of a normally functional mechanism to bias sensory processing towards attended stimuli, all stimuli receive much the same degree of sensory evaluation, and the irrelevant stimuli must then be actively discarded in a manner that creates a processing bottleneck. Perhaps because such a compensatory mechanism cannot be as quickly reset as the normal mechanism of selective attention, performance is impaired at tasks that demand rapid reconfiguration of perceptual resources.³³ An autistic deficit in rapid shifting of attention has been observed in cases of shifts between sensory modalities,³⁴ between spatial locations,^{35,30} and between object features.³⁶ Even when the demand for rapid shifting is eliminated and people with autism produce normal behavioural output, physiological measures remain abnormal, indicating an




Figure 1 Undifferentiated response in the autistic brain. Two different physiological measures in two different subject samples illustrate abnormally undifferentiated neural response in autism. A target presented at time zero cues a shift of attention between two streams of rapid, serially presented stimuli in left and right visual fields. Each graph plots the amplitude difference between response during left-to-right shifts and response during right-to-left shifts, comparing activity in left (solid) and right (dotted) visual cortices. Positive values denote greater activity during left-to-right shifts; negative values, right-to-left shifts. In normal adults, phase-locked EEG amplitude at the 9Hz frequency of stimulation reveals a transient response contralateral to the cue, followed by a more sustained response contralateral to the destination of the shift. On a longer time scale, the fMRI BOLD effect also reveals sustained response contralateral to the destination of the shift. In autism, activity in the two visual cortices is less clearly differentiated. Data are from Belmonte³⁰ and Belmonte and Yurgelun-Todd.²⁰

alternative mode of processing: frontal negativities associated with sustained attention are reduced or absent,³⁷ the frontal late positive component to peripheral visual stimuli is delayed,³⁸ and the visual P3b is highly variable,³⁷ with a somewhat low average amplitude.³⁸

Developmental connections

These abnormalities of perceptual processing point to a developmental explanation for higher-order abnormalities, an explanation that depends crucially on the idea of a developmental chain of abnormal function: when a developing brain is confronted with an abnormal constraint on information processing, it will evolve an abnormal organisation in order to accommodate that constraint.¹⁰ It is via such a chain of dysfunction that a core deficit such as degraded neural signal-to-noise could fan out into a welter of autistic behavioural abnormalities. From the earliest months of infancy, the flood of input generated by over-aroused, underselective primary processing

would overload nascent higher-order cognitive processes²⁰ — systems whose development may be being independently sabotaged by the same neuropathology that affects primary regions. Such an effect may explain the extension of sensory and motor activations in adults with autism into territories that normally subserve later-maturing cognitive functions.³⁹ Depending on its timing, such an error of neurocognitive development might underlie loss of cognitive skills or failure to develop skills.

Faced with this bottleneck in higher-order cognition, the developing and plastic brain would likely evolve a cognitive style that avoids reliance on high-level integrative processing and instead emphasises low-level features—a pattern typical of autistic attention and perception that Frith has termed weak central coherence.¹ Weak central coherence is of especial interest as part of an explanatory framework since since it predicts not only autism's cognitive impairments in integrative tasks but also its cognitive advantages in tasks that demand attention to detail.

People with autism perform better than normal on the Embedded Figures Test,⁴⁰ a task that demands recognition of individual features within spatial arrangements. Unlike normal subjects, they are not aided by presegmentation of patterns in the Wechsler Block Design subtest, and when they make errors, these are more likely to be ones of global configuration rather than local detail.⁴¹ In many high-functioning children with autism, lexical-to-phonological decoding based on words' small-scale features outpaces comprehension, producing a condition known as hyperlexia.⁴² Perhaps because they process faces as collections of individual features rather than as centrally coherent gestalts, children with autism are impaired at recognising unfamiliar faces^{43,44} and show a reduced or absent face-inversion effect.^{45,46} Again presumably because of intense processing of individual features, the normal levels-of-processing effect on memory is inverted in autism, with rote memory superior to normal, and memory for semantic associations impaired.⁴⁷ This piecemeal approach to perception is mirrored by a failure to generalise special skills to broader domains — for example, the calendar calculator who has no interest in other forms of arithmetic calculation.

Autism's weakened central coherence may thus be a secondary property, emerging in the interaction of normal cognitive development with abnormal neural information processing — an interaction that encourages an unusual cognitive dependence on low-level processing of individual details. Indeed, the presence of low-level perceptual abnormalities in autism⁴⁸ has contributed to a recognition that many higher-level cognitive abnormalities may best be characterised as the effects of a surfeit of local processing rather than any specific impairment in global processing,⁴⁹ and to an appreciation of the role of compensatory developmental changes surrounding altered perceptual functioning.⁵⁰ The possibility that

some of autism's cognitive symptoms may develop as compensatory or accommodative changes raises the possibility of targeted behavioural and pharmacological interventions — one could, for example, imagine an early intervention aimed at preventing the developing brain from relying so exclusively on its intact processing of local features, in somewhat the same manner as an eye patch prevents a child at risk for amblyopia from relying on the intact eye.

Weak central coherence may in turn form the cognitive underpinning of a wide array of developmental behavioural disturbances, by impairing the use of contextual information in complex perceptual and executive tasks,⁵¹ including theory-of-mind tasks⁵² that depend on an ability to apply the context contained in one's inner model of another person's mental state. Such an executive deficit may impede the development of joint attention and shared affect,^{53,54} processes in which response to stimuli depends crucially on social context. The resulting poverty of early social cognitive experience may perturb or prevent the further activity-dependent development^{12,13} of specialised modules or capacities for such tasks as face processing, language, and complex social relations. The end result would be a style of unsupervised learning founded on statistical associations rather than learning that is directed by the intentionality of others,⁵⁵ and consequently a preference for ritualised, scripted, and repeatable interactions (Table 1). Autism's surface symptoms might thus be understood as the developmental reaction of a normal human mind to abnormal neural hardware.

Anatomical correlates

Longitudinal studies using MRI volumetric and head circumference data point to the conclusion that autism involves transient postnatal macrocephaly⁵⁶ that may be the anatomical manifestation of one of the first links in this abnormal chain of development.

Table 1 Levels of autistic development

Preference for rule-based, predictable systems; repetitive behaviours; restricted interests; impaired social behaviour and communicative language	Behaviour
Possibly learnt dependence on low-level processing; weak central coherence, impaired executive function	Cognition
Lowered information capacity; altered activity-dependent maturation	Computation
Early brain overgrowth; altered microanatomy; intense and undifferentiated neural response	Anatomy and physiology
Genes governing neural and synaptic structure; regulators of gene expression; neurotransmitters and growth factors; immunological signalling factors; lipids affecting cell–cell signalling	Neural development

Many subtle genetic, biochemical, immunological, and other biasing factors at the neural level may fan in to pervert normal brain development onto an autistic course that leads to fundamentally altered neurocomputational properties. These neural alterations may fan out through activity-dependent processes and learnt cognitive strategies into a complex yet fairly deterministic set of behavioural effects, producing a syndrome whose surface behavioural properties, despite their diagnostic validity, may have only indirect aetiological significance.

Although nonstandardised measurements of head circumference must be viewed with some caution, the data currently available on newborns later diagnosed with autism or PDD-NOS suggest that head size at the time of birth is normal or perhaps even slightly smaller than normal.⁵⁷ By 2–4 years of age, 90% of these children have MRI-based brain volumes larger than the normal average,^{7–9} and group measures of head circumference have increased correspondingly. This abnormal brain growth is due primarily to excessive enlargement of cerebellar and cerebral white matter and cerebral grey matter.^{7,58} Even in older children, enlargement of superficial white matter tracts containing cortico-cortical fibres may persist, while internal capsule and corpus callosum are proportionately reduced.⁵⁸ Deviation from normal is so common and extreme that cerebellar and cerebral white matter volumes together with cerebellar vermis size accurately distinguish 95% of autistic toddlers and young children from normal children, and also accurately predict whether a young child with autism will have a low or high functioning developmental outcome.⁷ These 2–4-year-old autism patients show an anterior-to-posterior gradient of overgrowth, with frontal lobes being the largest.⁵⁹ This early abnormality creates a lasting legacy of increased head circumference throughout life, but, in most cases, not a lasting macrocephaly. By adulthood, then, macrocephaly is not typically present in autism, and brain volumes tend to be near normal. The increase in the volume of cortical grey matter may reflect a failure of synaptic pruning or a surfeit of synaptogenesis, and may thus be the earliest gross anatomical manifestation of a pervasive abnormality in the development of neural assemblies. Of equal potential importance, the increased volume of local white matter projections suggests abnormality in the normal postnatal process of rapid myelination.

In characterising this underlying abnormality, it is important to note that a general deficit in development may interact with normal developmental gradients to produce an anatomically and functionally specific pattern of deficits. Myelination, for example, is not uniformly controlled across the cerebral hemispheres, but instead develops in a posterior-to-anterior direction. The persistence of myelination into the third decade of life in frontotemporal but not occipitoparietal fibre tracts^{60,61} indicates that oligodendrocyte regulation differs regionally. Likewise, changes in the development of neuronal populations can arise in a regionally selective manner: in a targeted mutation of the hepatocyte growth factor signalling system, for example, deficits of GABAergic neurons appear only in frontal and parietal cortices, and only in the parvalbumin-containing subpopulation of cells.⁶² In terms of cellular and molecular relationships just as in the case of cognitive ones, it may be fruitful to view autism as a product of the interaction of normal development with abnormal constraints. Observations of abnormal patterns of early brain growth suggest that at least a portion of this

interaction occurs postnatally. This postnatal time frame for pathogenesis offers hope of early biological interventions, if the genetic and neurochemical determinants of abnormal growth can be identified.

Neurobiological bases

Genes

It has become increasingly clear that genetic factors are very significant determinants of autism pathophysiology. The risk that another sibling will be born with autism to parents who have already had an autistic child is approximately 4.5%.⁶³ Given recent estimates of population prevalence for autism,⁶⁴ this statistic represents a sibling recurrence risk over 20 times the risk for the general population. Moving from siblings in general to identical twins in particular, the increased risk of concordance for autism rises from 20-fold to over 200-fold. Such a large differential suggests not only the involvement of multiple genes, but also a multiplicative effect among these genes. For example, if there were five genes involved, a 20-fold increase could be accumulated from risk multipliers as small as 1.8 for each gene. Although some estimates of the number of interacting genetic loci in autism are as low as 2–10,⁶⁵ others range from over 15 to over 100.^{66,67}

This multiplicative mode of inheritance carries implications for the nature of the genetic factors involved, for the experimental discriminability of each individual factor, and for the potential of interventions targeting these factors. Multiplicative effects arise from interactions between individual genes, and the susceptibility factors for autism are therefore likely to influence gene expression or to encode subtle functional alterations in proteins that participate in regulatory networks. Multiplicative inheritance also means that the small effect of each gene by itself will be difficult to identify and to confirm; each genetic variant is likely to act as ‘the straw that breaks the camel’s back’, innocuous by itself but pathological in concert. Although these small effect sizes will be difficult to discern, the advantage in terms of treatment is that intervening to restore regulation to a single gene or to a small set of genes may diminish the multiplicative effect enough to yield large preventative or therapeutic effects. This situation in which the disorder may be approached via any of several therapeutic targets stands in contrast to monogenic disorders where there may not be an obvious therapeutic strategy before decades of basic work (e.g. Huntington’s disease).

A further consequence of the multiplicative model is that the prevalence of individual risk alleles in the general population will be high. Most if not all of these autism ‘risk’ alleles are likely to have some adaptive value, in cases where they do not lead to autism. In some cases this adaptive value would be obvious (e.g. enhancement of focused attention or other elements of neuropsychological function). In other cases, the benefits to humanity of the existence

of these alleles may be more difficult to determine, but are likely to be present.

Although review of the current status of identifying genetic risk factors for autism is beyond the scope of this manuscript, several thorough reviews are available.^{14,68–70} Two relatively small regions, on 15q11–q13 centred around the GABA_Aβ₃ receptor subunit gene (*GABRB3*) and near the serotonin transporter (*SLC6A4*) on 17q11.2, are locations where more than two, but not all, studies have shown family-based association with autism. In addition to 17q, several other regions of the genome including 2q and 7q appear involved in the larger syndrome based on convergence from several studies. Fine mapping of these regions should be a priority in addition to generating larger samples in which two or more siblings have autism in a family (e.g. the Autism Genetic Resource Exchange (AGRE)).⁷¹

At least four X chromosome loci have already been implicated in autism, including neuroligin 3 (*NLGN3*), neuroligin 4 (*NLGN4*), *FMR1* (see below), and *MECP2*. Although rare, a possibly functional missense mutation has been identified in *NLGN3* in an affected sibling pair, and a *de novo* nonsense mutation of *NLGN4* has been found in affected siblings and their unaffected mother.⁷² Discrepancies between the affected status of the mother and offspring are somewhat difficult to interpret since, as the authors note, strong sequence conservation exists between *NLGN4* and *NLGN4Y*. Nevertheless, the association of neuroligins with autism is of great interest in light of the idea that autism's pathophysiology may begin with abnormal neural connectivity.

The first truncating mutations in an autism-related disorder were reported when mutations in *MECP2* were identified in Rett syndrome.⁷³ The function of *MECP2* is to turn off several genes whose promoters have been methylated. Therefore, in addition to *FMR1* and *UBE3A* discussed below, mutations in *MECP2* contribute to neurobiological dysfunction due to dysregulation of networks of temporally and spatially regulated genes. The recent finding of 2 *de novo* mutations of *MECP2* in a screen of 69 females with autism⁷⁴ shows that MeCP2, and perhaps its regulatory targets, are likely to be a contributing factor in autistic pathology.

In summary of the current findings, there is as yet no confirmed genetic finding in autism that has been explained in terms of its specific relation to brain development. In order to understand what genetic factors may influence the developmental processes that lead to autism, it is useful to focus on syndromes whose symptoms overlap with those of autism and which may be more tractable in terms of our current knowledge of biological cause and effect.

Proteins that regulate gene expression

One such symptomatically overlapping disorder is Fragile X syndrome (FXS). FXS is the most common inherited form of mental retardation and second only to Down syndrome overall. Its neurobehavioural

phenotype is characterised by some combination of mild to severe cognitive impairment, attention deficit, anxiety, seizure susceptibility, communicative disorders, and stereotypic behaviours. In addition, recent reports have suggested that 25–40% of individuals with FXS also meet diagnostic criteria for autism.⁷⁵ Studies of children with autism have shown a concurrence of FXS with autism of approximately 2%, with one study finding the Fragile X mutation to be the most frequent chromosomal anomaly associated with diagnosed autistic cases.⁷⁶ In many instances, the behavioural profiles observed in FXS seem indistinguishable from those of idiopathic autism — although some studies have noted distinct differences especially in the realm of social and communicative skills.⁷⁷

FXS is caused by the silencing of a single gene (*FMR1*)⁷⁸ that codes for the Fragile X Mental Retardation Protein (FMRP), an RNA-binding protein.⁷⁹ FMRP binds to numerous mRNA cargoes, including its own mRNA, and has been hypothesised to regulate the expression of a specific set of genes in neurons. When FMRP is absent, the expression of these genes is altered and the FXS phenotype is observed. A critical feature of FXS, therefore, is that what is in one sense a single-gene disorder is more proximally the result of a disruption of complex patterns of expression of many genes. Using a novel technique, Miyashiro *et al*⁸⁰ have recently demonstrated that multiple classes of mRNA molecules are bound to FMRP in neurons. In light of the high incidence of autistic behaviours in FXS, the data set of approximately 80 genes whose mRNAs bind to FMRP was screened to reveal 15 that map closely to suspected autism susceptibility loci. It is interesting and reasonable to speculate that polymorphic variations in these genes, and perhaps others to be determined, may be related to the variable autistic phenotype observed in many patients with FXS.

An examination of FMRP's expression and association with polyribosomal machinery in the brain leads to three important concepts. First, some of the protein synthesis that involves FMRP occurs at synapses in response to Group I metabotropic receptor activation.⁸¹ (Since not all FMRP-expressing cells receive synaptic input, though, it is likely that not all protein synthesis involving FMRP is synaptic.) Second, FMRP itself is synthesised in response to activation of metabotropic glutamate receptor subtypes 1 and/or 5. Third, this process requires FMRP, since synaptic activity-dependent protein synthesis is greatly reduced in the FraX knockout mouse.⁸² An interesting *in vivo* correlate of this observation is that the proportion of dendritic spines that contain polyribosomal aggregates is reduced in the cortices of knockout mice. Therefore, one physiologically based hypothesis is that FMRP regulates the local expression of a subset of genes by controlling their translation in response to neuronal activity.

Behavioural exposure to a complex environment increases FMRP expression in rat visual cortex,⁸³ as

do physical activity in the case of somatomotor cortex⁸³ and whisker stimulation in the case of barrel cortex.⁸⁴ Knockout of the *FMR1* gene in mice increases dendritic spine density in visual⁸⁵ and somatosensory⁸⁶ cortices. Human autopsy studies^{85,87} reveal an overabundance of long, thin spines, and an increase in the number of spines overall, suggesting a failure of the synapse elimination that would normally occur during early development. These neocortical findings in FXS contrast with reduced hippocampal dendritic branching observed in two autistic brains;¹⁷ larger-scale studies of dendritic morphology in autism are needed to address this issue.

Among other loci associated with regulatory proteins, the abnormalities in 15q11–q13 are of especial interest because of the association of 15q11–q13 with two neurogenetic disorders, Prader–Willi syndrome (PWS) and Angelman syndrome (AS), and overlapping clinical features between AS and autism. The AS gene, *UBE3A*, is maternally expressed only in brain tissue and codes for a ubiquitin protein ligase, an enzyme that can regulate the levels of many intracellular proteins by labelling them for ubiquitin-mediated degradation. *UBE3A* abnormalities thus are capable of producing a wide range of fan-out effects.

The majority of patients with PWS or AS have a deletion of 15q11–q13, on the paternal chromosome in PWS and on the maternal chromosome in AS.⁸⁸ In contrast, a smaller fraction of PWS and AS patients have uniparental disomy for chromosome 15, with two paternal chromosomes causing AS and two maternal chromosomes causing PWS. In each case the balance between maternally and paternally derived genes is altered; however, in the case of deletion the aetiology is clearly genetic, whereas in the case of uniparental disomy it is epigenetic: in these disomic individuals there is no abnormality of the genomic sequence, yet the phenotype is indistinguishable from that caused by genetic deletion. Epigenetic disease of this sort may be more common than previously considered.⁸⁹ Similar phenomena may be operating in autism, with both genetic and epigenetic alterations contributing to autism susceptibility.

Despite the association of autism with maternal duplication of 15q11–q13, interstitial duplications in the homologous region on the paternal chromosome are associated with a relatively normal phenotype. These data strongly suggest that there is an imprinted, maternally expressed gene or genes within 15q11–q13, epigenetically induced overexpression of which can contribute to autism. The best studied form of epigenetic modification is DNA methylation, and abnormalities of DNA methylation and/or its effects are implicated in several genetic diseases whose clinical features overlap with those of autism, including FXS, PWS, AS, and Rett syndrome. The dynamic changes in DNA methylation that occur during early embryonic development and during germ cell development provide ample opportunity

for germline or somatic errors in epigenetic processes, ‘epimutations’.⁹⁰ If an abnormality of DNA methylation were proven in autism, an immediate therapeutic intervention could be explored using drugs or dietary manipulations known to alter DNA methylation, such as folate supplementation.

Success in modelling AS in *UBE3A* knockout mice suggests that murine 15q11–q13 manipulations may also hold promise for the development of an animal model of autism. Mice with maternal deficiency of *UBE3A* recapitulate the human AS phenotype with motor dysfunction, seizures, deficiency in contextual learning, and impairment in hippocampal long-term potentiation.⁹¹ The role of 15q11–q13 in autism can be dissected by making mice with various locus-specific duplications⁹² of the homologous PWS/AS domain. This approach may produce a valid mouse model for autism even before a specific autism-related gene within 15q11–q13 is conclusively identified.

γ-Aminobutyric acid

The 15q11–q13 region also codes for several subunits of the GABA_A receptor, an ionotropic receptor whose hyperpolarising effect is mediated by chloride. *GABRB3*, *GABRA5* and *GABRG3* (encoding the GABA_A receptor's β_3 , α_5 , and γ_3 subunits, respectively), all are clustered within 15q11–q13. GABAergic interneurons have a special role in establishing the computational architecture of cortical columns,^{93,94} and may be particularly vulnerable to developmental errors since they arise from a different portion of the neural tube than the excitatory cells with which they integrate.⁹⁵ The increased incidence of epilepsy in patients with autism and 15q11–q13 duplications is consistent with the involvement of GABA. Hippocampal GABA_A receptor binding in autism is abnormally low,⁹⁶ as are platelet GABA levels.⁹⁷

Recent genetic studies in mice suggest molecular mechanisms that could underlie this GABAergic pathology.⁹⁸ Mice lacking the *GAD65* gene, encoding an enzyme that makes GABA, have defective cortical plasticity that can be corrected with a GABA agonist.⁹⁹ Mutations in the *Dlx1* and *Dlx2* genes disrupt development of most telencephalic GABAergic neurons.^{95,100} It is worth noting that the human locus that has the highest LOD score for autism susceptibility (D2S2188 on chromosome 2q) maps very close to *GAD65* as well as *Dlx1* and *Dlx2*.¹⁰¹ Furthermore, the autism susceptibility locus (D7S477) on chromosome 7q maps within about six megabases of *Dlx5* and *Dlx6*. These genes are also implicated in regulating forebrain GABAergic development.^{102–104} Also in this region is the gene for reelin, a protein expressed in cortical GABAergic neurons.¹⁰⁵

One of the GABA_A receptor subunit genes in particular, *GABRB3*, is highly expressed during brain development in rats,¹⁰⁶ and its deletion in mice disrupts GABA-related pharmacology and electrophysiology and produces behaviours reminiscent of

autism.¹⁰⁷ Homozygous disruption of *GABRB3* in mice reduces GABA_A receptor binding by half, and GABA-activated chloride current by 80%, and similar, lesser effects are observed in heterozygotes.¹⁰⁸ As a result, *GABRB3* knockout mice have epileptiform EEG containing high-amplitude slow and sharp waves, and develop overt seizures as they mature.^{108,107} Behaviourally, *GABRB3* knockouts show hypersensitivity to thermal and tactile stimuli,¹⁰⁹ hyperactivity and motor stereotypies,^{108,107} poor motor coordination,¹⁰⁷ and lengthened cycles of rest and activity.¹⁰⁷ EEG spectral characteristics during slow-wave sleep are abnormal.¹¹⁰ There are also cognitive deficits, as measured by abnormalities of passive-avoidance conditioning and contextual fear conditioning.¹⁰⁷ Mothers homozygous for the *GABRB3* knockout fail to engage in normal nurturing behaviour, even towards their wild-type pups.¹⁰⁸ These similarities to autism suggest either a direct involvement of *GABRB3* in autism, or some GABA pathology that shares physiological or developmental effects with the *GABRB3* knockout. Efforts should therefore focus on studying known genes in known autism susceptibility loci that affect development and/or function of the GABAergic system. This analysis will identify SNPs and potential function-altering mutations. Furthermore, GABAergic agonists should be considered as potential therapeutic agents for autism.

Acetylcholine

GABAergic dysfunction can be produced not only by direct alterations in GABA systems but also by changes in neuromodulation of GABAergic neurons. Several neuromodulators may be involved in such changes, potentially with synergistic effects. Abnormal developmental changes in the population of septal neurons in autism suggest a cholinergic abnormality: septal neurons are excessive in younger and reduced in older individuals with autism.¹⁶ Acetylcholine affects performance during sustained attention,¹¹¹ possibly by shifting the dynamics of cortical networks so that afferent influence predominates over intracortical inputs.¹¹² In mice, knockout of the α_4 nicotinic subunit produces reduced antinociception and increased anxiety;^{113,114} abnormal pain sensitivity and anxiety both are features of the autistic syndrome. In addition, nicotinic receptors are essential for normal early synaptic development¹¹⁵ and thus nicotinic dysfunction may produce abnormal neural microarchitecture.

The $\alpha_4\beta_2$ nicotinic acetylcholine receptor is decreased in autopsied brains of adults with autism.^{116,117} This deficit is most pronounced in the cerebral neocortex, where the $\alpha_4\beta_2$ receptor subtype has an important regulatory effect on GABAergic neurons.¹¹⁸ The decrease is selective; the other principal nicotinic receptor subtype, α_7 , is not involved. Although normal levels of choline acetyltransferase suggest that cholinergic input to the cerebral cortex and the cerebellum is intact, the level of BDNF in the basal forebrain has been observed to

be three times higher than normal.¹¹⁷ In addition to its role in GABAergic development, BDNF is involved in enhancing cholinergic transmission¹¹⁹ and in promoting the survival of developing cholinergic neurons of the basal forebrain.¹²⁰ This BDNF abnormality at the major source of forebrain cholinergic projection may therefore be significant for cholinergic function.

As these neurochemical results come from adult brains, it remains to be seen whether nicotinic abnormality is present at early stages of autistic development. Cholinergic dysfunction may be an indirect contributor to autistic development via its influence on GABAergic neurons, a correlate of prior GABAergic dysfunction, or a direct contributor via its influence on synaptic development. *In vivo* studies at early ages, using PET and MR spectroscopy, will give further information on the role of acetylcholine in autism. Pharmacologic therapies targeting the cholinergic system may be of value; there has been one report of success using the acetylcholinesterase inhibitor donepezil to treat autistic symptoms of irritability and hyperactivity.¹²¹

Serotonin

There has been a continuing interest in the role of serotonin (5-hydroxytryptamine, 5-HT) in autism since the initial report of elevated levels of platelet 5-HT in individuals with autism.¹²² An increasing awareness of 5-HT's critical involvement in guiding neurodevelopment and in modulating sensory input and arousal has provided a convincing theoretical basis for 5-HT's role in the aetiology and pathophysiology of pervasive developmental disorders. Much of the embryonic expression of 5-HT appears related to its role as a growth factor and regulator of neuronal development.¹²³

As expected from its phylogenetically ancient role in neurodevelopment and neural transmission, and its extensive CNS projections, 5-HT has been shown to play a key role in a variety of behaviours and processes, including sleep, mood, arousal, aggression, impulsivity, and affiliation.¹²⁴ Reduced serotonergic function has been associated with worsened sleep, depressed mood, altered arousal, increased aggression, greater impulsivity, and reduced social behaviour. Genetic data have connected 5-HT-related genes to disorders defined by symptoms in several of these areas and it is clear that the serotonergic system is intimately interconnected with GABAergic and glutamatergic neurons throughout the brain. Serotonin's especially rich innervation of limbic areas critical for emotional expression and social behaviour provides additional support for its possible involvement in autism.

Empirical studies of 5-HT in autism include pharmacological treatment and challenge studies, biochemical/neurochemical studies of 5-HT and related compounds, and genetic studies of 5-HT-related genes. Selective 5-HT reuptake inhibitors target the 5-HT membrane transporter and are frequently used in autism. Risperidone, another

widely used agent, exerts at least some of its effect at the 5-HT_{2A} receptor.¹²⁵

Platelet hyperserotonemia has been especially well studied and is generally considered the most robust and well-replicated biological finding in autism.^{126,127} Most studies have reported group mean elevations of 25–50% in platelet serotonin in persons with autism. The mechanism of the alteration and its possible relationship to brain abnormalities remain unknown. The platelet does not appear to be exposed to greater amounts of 5-HT; attention has therefore focused on handling of 5-HT within the platelet. To date, no clear alteration in the platelet has been identified although there is some suggestion that uptake may be increased in some subjects with increased platelet levels.

Genes encoding a number of the components involved in 5-HT neural transmission have been examined as possible risk factors for autism and associated behaviours and disorders including social phobia, bipolar disorder and obsessive–compulsive disorder.¹²⁸ Research in autism has focused on the influence of 5-HT transporter gene (*SLC6A4*) variants. Although taken together the studies do not convincingly support a role for *SLC6A4* variants in determining overall risk to autism,¹²⁹ investigators are now examining linkage and association to the severity of specific aspects or domains of autistic behaviour.^{130,131}

At present, the areas of neuroimaging and post-mortem brain research appear to offer the greatest potential for elucidating the role of serotonin in autism. Reciprocal interchange between imaging, neuropsychological, and postmortem research should be especially useful and illuminating. Work on the mechanism of the platelet hyperserotonemia may provide critically important information regarding possible central 5-HT dysfunction. The identification of a delineated cell type with elevated 5-HT might be best exploited by gene or protein expression technology.

Lipids

Another genetic condition that shares autistic symptoms is Smith–Lemli–Opitz syndrome (SLOS), an autosomal recessive, multiple malformation/mental retardation syndrome¹³² with an estimated incidence among individuals of European ancestry of one in 40 000 to one in 60 000 births and a probable average carrier frequency of 1%¹³³. Principal abnormalities include a characteristic facial appearance, microcephaly, hypotonia, postnatal growth retardation, 2–3-toe syndactyly, and hypogenitalism. In 1993, SLOS was shown to be caused by a defect of cholesterol biosynthesis at the level of the 7-dehydrocholesterol reductase.¹³⁴ This defect impairs the conversion of 7-dehydrocholesterol (7-DHC) to cholesterol, causing an increased level of 7-DHC in blood and tissues, and, in most patients, decreased blood and tissue cholesterol levels. A major consequence of these biochemical abnormalities is the alteration of normal embryonic

and foetal somatic development, causing postnatal abnormalities of growth, learning, language, and behaviour.

Clinical data show that SLOS is associated with autism, and suggest that cholesterol supplementation ameliorates autistic behavioural symptoms. Of 17 subjects with SLOS for whom the Autism Diagnostic Interview (ADI-R)¹³⁵ algorithm questions were administered, nine (53%) met the ADI-R criteria for autism.¹³⁶ Of the nine subjects who began cholesterol supplementation before the age of 5.0 years, two (22%) met the ADI-R algorithm criteria for autism at age 4.0–5.0 years. Of the remaining eight subjects who began supplementation after the age of 5.0 years or had not yet started supplementation, seven (88%) met the ADI-R algorithm criteria for autism.

Despite its behavioural similarities, the extent to which SLOS may share neurobiological mechanisms with non-SLOS autism remains unclear. Individuals with SLOS manifest some anatomical abnormalities¹³³ reminiscent of those often seen in autism: hypoplasia of the corpus callosum, and of the cerebellum and particularly the vermis. However, the developing macrocephaly in autism contrasts with a microcephaly in SLOS present from birth and persisting into later life. The comparison between SLOS and autism at the level of microanatomy remains an open question which could be usefully explored by quantitative neuropathological studies. Even in the absence of proven shared mechanisms of neuropathology, SLOS's comorbidity with autism does suggest lipid-associated pathways that may be disrupted in non-SLOS autism and which may be examined for further clues. Abnormalities of the lipid membrane can affect membrane-associated proteins involved in neural or developmental signalling, and individuals may also have dysfunctions of sterol or steroid metabolism, beginning *in utero* or later in life.

Immunological signalling

In addition to specific neurotransmitter systems and metabolic pathways, recent studies have suggested that genes within the major histocompatibility complex (MHC, or HLA in humans), on chromosome 6p21.3, may encode predisposing factors in autism¹³⁷ (but see Rogers *et al*¹³⁸). In particular, an unusual number of people with autism may share all or part of the extended MHC haplotype B44-SC30-DR4.¹³⁷ Evidence also exists for a link between autism and a null allele of the C4B gene, in the class III MHC region, and correspondingly low levels of C4b protein,¹³⁹ which is essential in activation of the classical complement pathway. Perhaps related to these immunogenetic results in autism are findings of an elevated incidence of immune disorders in patients and in first-degree relatives,¹⁴⁰ and often abnormal humoral immune and autoantibody responses,¹⁴¹ abnormal cell-mediated immunity and abnormal T-cell populations and functions,¹⁴² reduced NK-cell activity,¹⁴³ and lower Th1 and higher Th2-like cytokines.¹⁴⁴ Interest-

ingly, immune dysfunction and strong genetic linkage to the MHC are seen in dyslexia, another neurodevelopmental disorder that is similarly far more prevalent in boys.^{145,146} It appears that abnormal immune responses may be predisposing but not sufficient to cause autism, since nonautistic first-degree relatives often share these abnormalities.¹⁴⁷ These and other immunogenetic and immunological correlates in autism may reflect a causal role for immunological factors, or alternatively may arise from linkage disequilibrium with nearby, undiscovered loci or from metabolic relationships with other susceptibility factors. Of note in connection with this latter possibility are the dependence of MHC signalling on peptide fragments produced by ubiquitin ligase, and the immunomodulatory effect of serotonin,¹⁴⁸ both substances mentioned previously.

In support of a causal role for immunological liabilities, some maternal viral infections are known to increase the risk for schizophrenia and autism, and maternal influenza infection in mice produces profound anatomical, motor, and other behavioural defects reminiscent of autism, including anxiety in novel situations and early postnatal macrocephaly.^{149,150} Infection in turn could lead to changes in expression of cytokines¹⁵¹ or neuronal class I MHC,¹⁵² or to production of autoantibodies.¹⁵³ While it is unknown if autism is correlated with a change in neuronal MHC expression, CNS autoantibodies have been detected in mothers¹⁵³ as well as in autism patients themselves.¹⁴¹ It is worth noting that viral or bacterial infections are suspected in the induction of many autoimmune diseases, perhaps due to molecular mimicry or to sequelae of persistent subclinical infection.¹⁴⁰

Although immunological involvement in autism has historically been conceptualised in terms of altered response to infection or altered susceptibility to autoimmune attack, an alternative hypothesis arises in light of the recent discovery that class I MHC, in addition to its well-characterised role in immune function, is expressed in neurons and is critical for normal brain development and function.^{154,152} This novel finding suggests that defects in MHC function could give rise, in parallel, to both immunological and neurodevelopmental dysfunctions.¹⁵⁵ Although originally not thought to be expressed by normal, uninjured neurons, class I MHC was identified in an unbiased screen for genes involved in activity-dependent refinement of developing visual projections.¹⁵⁴ Here, as in many other regions of the developing brain, initial projections are large and imprecise, and patterned neuronal activity arising in the periphery is necessary for the removal of inappropriate connections and stabilisation of appropriate ones. This process is critical to achieving mature patterns of connectivity, and in mammals occurs in early postnatal life. Strikingly, class I MHC mRNA is regulated by the spontaneous activity that drives refinement of the developing visual system,¹⁵⁴ and is expressed by neurons precisely at the times

and places of widespread activity-dependent structural and functional plasticity, both during development and in the adult.^{154,152}

This positive association between MHC signalling and synaptic development is reinforced by the negative effects of MHC knockouts. Mice deficient for class I MHC signalling retain the immature pattern of visual connections, presumably due to a failure of activity-dependent refinement.¹⁵² In addition, hippocampal synapses in these mice are not weakened in response to patterned activity, and instead are inappropriately strengthened. Both of these defects are also found in mice lacking CD3 ζ , a component of many known receptors for class I MHC.¹⁵² These changes in plasticity are not a nonspecific effect of immune compromise, since neural plasticity is normal in even more severely immunocompromised (RAG1^{-/-}) mutant mice.¹⁵² Thus class I MHC (along with its associated signal transduction machinery) is required, either developmentally or acutely, for activity-dependent synaptic weakening and removal of inappropriate connections, changes that are crucial for the establishment and maintenance of normal neural connectivity.^{152,155} Patterns of MHC gene expression that vary with neuron type, brain region, and age¹⁵² may interact with a general abnormality in MHC signalling to produce specific deficits in connectivity.

The studies linking immune genes and immunological functions to autism are fragmentary and a topic of heated debate. Methodological differences, small sample sizes, and a lack of appropriate control groups, as well as likely heterogeneity in aetiology and pathology, all hamper interpretation of conflicting studies. Causal heterogeneity in particular will likely frustrate attempts to determine genetic, functional, and anatomical correlates until other, perhaps biochemical, diagnostic criteria are developed to classify causal subtypes of autism. To that end, the hypothesis that MHC signalling is involved in the aetiology of a subset of cases of autism suggests candidate markers and neural substrates that may identify one such population. It would be of interest to determine whether neurons that may be affected early during autistic development, such as cerebellar Purkinje cells and granule cells, express high levels of MHC around the time of onset. In addition, it would be of great value to know if MHC is expressed in abnormal patterns or levels in the developing autistic brain as compared to the normal brain, although such experiments await the further refinement and validation of animal models.

Animal models

Although several primate models of autism have been developed,¹⁵⁶ research on neurodevelopmental abnormalities and treatments for autism has had to cope with a dearth of nonprimate animal models. Targeting relatively simple behaviours in rodent models has proven useful in the development of pharmacological

targets in other neuropsychiatric diseases such as schizophrenia and affective disorders.^{157,158} Establishing the face, predictive, and construct validity of an animal model of autism may prove extremely useful in advancing understanding of autism's neuropathology and in screening potential therapies. Approaches to animal models of neuropsychiatric disease involve modelling the aetiology or pathophysiology of the disease (e.g. cerebellar pathology) or modelling particular behavioural attributes (e.g. abnormal social interactions or deficient sensorimotor gating).

If people with autism are hyper-responsive to sensory stimuli, then existing methods of examining sensory responsiveness may be useful in defining endophenotypes and developing animal models of autism. One approach to measuring sensory processing arises in the context of sensorimotor gating. Prepulse inhibition (PPI) of the startle response is a cross-species measure of the normal decrement in startle when a barely detectable prestimulus immediately precedes (30–500 ms) a startling stimulus.¹⁵⁹ PPI appears to reflect the activation of a ubiquitous centrally mediated behavioural 'gating' process, and has been widely applied in studies of information processing and cognition in animals and humans. In particular, the inhibitory processes activated by the weak 'prepulse' and the resulting decrement in startle amplitude have been used as an operational measure of sensorimotor gating. Deficits in PPI have been observed in schizophrenia¹⁶⁰ and several other neuropsychiatric conditions, and schizophrenia-like deficits in PPI have been mimicked in animals using both pharmacological¹⁶¹ and anatomical manipulations.¹⁶² Studying PPI has enabled a focus on well-defined measures of information processing having substantial homology among different species and, in the case of schizophrenia, significant predictive validity for treatments.¹⁶³

Although an earlier study of autism showed no abnormality in PPI,¹⁶⁴ a more recent, parametrised examination revealed a selective impairment in the inhibition of startle response at high prestimulus amplitude and longer prestimulus-to-stimulus intervals.¹⁶⁵ While normal subjects showed the typical pattern of increased prepulse inhibition at higher prestimulus intensities (12 vs 4 dB) and longer interstimulus intervals (120 vs 30 ms), people with Asperger syndrome did not. This failure to make use of extra processing time to rapidly modify response bias is reminiscent of results on slowed shifting of attention in autism,³⁵ and the absence of an effect of prepulse amplitude suggests abnormal sensory responsiveness—a possibility supported by skin conductance findings of abnormally high tonic arousal¹⁶⁶ and abnormally high phasic response to stimuli¹⁶⁷ in autism. Similar findings of high arousal¹⁶⁸ and high responsiveness¹⁶⁹ in FXS support the idea that these abnormal sensory phenomena may be markers of abnormal neural development.

Sensorimotor gating abnormalities similar to those in human neuropsychiatric conditions have been

produced in rats by a variety of neurodevelopmental manipulations.¹⁵⁸ The developmental model most extensively studied for its effects on PPI has been postweaning social isolation, a manipulation that induces profound abnormalities in behaviour, drug responses, and neurochemistry.¹⁷⁰ Neurodevelopmental animal models like those developed for schizophrenia are now being brought to bear on autism. Some of these autism models are based on prenatal exposure to teratogens such as Borna disease virus¹⁷¹ or valproic acid.¹⁷² Others derive from findings of abnormal cerebellar anatomy in people with autism, and include both mutant animals with specific cerebellar malformations^{173,174} and animals with surgical lesions of the midline cerebellum.¹⁷⁵ Several such cerebellar models have begun to find application in the study of sensorimotor gating and other behaviours relevant to autism: deficits in PPI have been observed in heterozygous reeler mice¹⁷⁶ and in mice homozygous for the cerebellar deficient folia (cdf) mutation.¹⁷⁷

A further model is based on the hypothesis of low signal-to-noise as a basis of autistic brain development: if this is the case, developmental errors similar to those in autism ought to be able to be induced by manipulating signal-to-noise directly, independently of any neurochemical antecedents. A straightforward way of implementing such a direct manipulation is to supply the developing brain with consistently noisy sensory inputs. In rats reared in continuous 70 dB acoustic noise, neurons in primary auditory cortex retain into adulthood the immature pattern of broad, high-frequency tuning curves and imprecise tonotopy typical of the earliest stage of auditory development¹⁷⁸—a pattern similar to that revealed by psychoacoustic tests in people with high-functioning autism.⁴⁹ In addition to retarding the emergence of normal activity-dependent patterns of neural tuning, developmental exposure to noise prolongs the critical period during which any input, regardless of behavioural context, is significant for activity-dependent plasticity.¹⁷⁸ A delay of this transition from unconditional plasticity to context-dependent plasticity may underlie the ease with which people with autism learn arbitrary associations, and the difficulty with which they incorporate behavioural context into such learning. Furthermore, a delayed and abnormal closing of this critical period may be the trigger for the onset of autistic regression during the second or third year of life.

Inevitably, animal models will play an important role in future research on the causes and cures for autism. There is a need for creative translational designs wherein tests demonstrating specific brain-behaviour relationships in children with autism are formatted for application in animal models. For instance, a recent human study showed that when allowed to explore freely an open area containing novel objects, children with autism spent less time exploring the novel information than normal children, and that the more abnormal the exploration

behaviour, the smaller the cerebellar vermis.¹⁷⁹ Such a study design can be easily formatted for testing animal models of candidate genetic or nongenetic causes of autism, and in fact several candidate models already exist. The GS guinea-pig, a mutant with malformation of cerebellar vermal lobules VI and VII, shows decreased exploratory behaviour,¹⁷³ as do Purkinje cell degeneration mutant mice.¹⁸⁰ Specific loss of Purkinje cells in cerebellar vermal lobules VI and VII in L1CAM knockout mice is associated with decreased exploration and stereotyped circling in a novel environment.^{181,182} Rats with cerebellar lesions show deficits in long-term habituation of the acoustic startle response¹⁸³ and increased spontaneous motor activity and perseverative behaviour.¹⁷⁵ As the definition of human behavioural endophenotypes in autism proceeds, measurable, homologous behaviours can be quantified in animal models. Prepulse inhibition and other forms of startle modulation (e.g. fear potentiated startle) may be useful in constructing such animal behavioural homologues.

Research imperatives

Phenotypes within and beyond the diagnosis

To those who treat patients with autism spectrum disorders, or who work with them as researchers or caregivers, it can often seem as if there are as many kinds of autism as there are people with autism. Since the diagnosis of autism rests on broad and entirely behavioural criteria, studies whose inclusion criteria follow the diagnostic criteria are liable to recruit subject groups that are heterogeneous in terms of ultimate causes. Reducing this heterogeneity demands a more detailed taxonomy, extending not only within the diagnosis but also outside it. The accepted wisdom has been to restrict studies to only the most severe cases — for example those patients who satisfy both ADI-R and ADOS criteria and whose clinical diagnoses exclude Asperger syndrome and PDD-NOS. Although this strategy certainly reduces heterogeneity, it puts blinders on efforts to identify behavioural endophenotypes. In contrast, broadening studies beyond the strict diagnosis of autism holds a great deal of promise for identifying which components of the autistic syndrome are genetically transmitted, and how these components interact. The early results of such work reveal familial patterns of repetitive behaviours, impaired nonverbal communication, and impaired or delayed development of phrase speech, but not social interaction or verbal communication.¹⁸⁴

Autism may well occur when several root factors combine to produce a core dysfunction (a dysfunction that we have suggested may involve neural signal-to-noise — to a degree that brings on a grand change in developmental course and produces autism's many symptoms. Information on the abnormalities surrounding this critical developmental event becomes much more valuable when it can be contrasted with information on what happens when the event is

avoided. Such a contrast can be obtained by studying siblings and other family members of patients with autism, people who presumably share some of the genetic susceptibility factors but in whom those factors have not become magnified into the full syndrome of autism. A wealth of behavioural data suggests that such factors are operative in first-degree relatives and do produce subclinical abnormalities. Siblings of autistic children show a cognitive profile reminiscent of that of autism itself, with superior spatial and verbal span, poor set-shifting, poor planning, and poor verbal fluency.¹⁸⁵ Parents of autistic children perform in the superior range on the Embedded Figures Test,¹⁸⁶ visual search tasks,¹⁸⁷ and other tasks that require processing of parts and details,¹⁸⁸ but are below normal performance at inferring mental state from facial expression,¹⁸⁶ a task that demands configural and integrative processing. In addition, parents share difficulties in pragmatic language tasks,¹⁸⁹ impairments in some tasks that tap executive function,¹⁹⁰ and autistic personality characteristics such as rigidity, aloofness, and anxiety.¹⁹¹ Many first-degree relatives show a disparity between performance IQ and verbal IQ, with the performance score being lower^{192,193,189} due to impairment on Picture Arrangement and Picture Completion, both of which demand attention to global, contextual information. These subtle characteristics of the broader autism phenotype are visible in the cognitive skills that relatives tend to develop: occupations in engineering, which demands meticulous attention to detail, are over-represented in the fathers and grandfathers of people with autism¹⁹⁴ and, conversely, the incidence of autism is increased in the families of engineers, mathematicians, and physicists.¹⁹⁵ Siblings are at greater risk than the general population for a wide array of cognitive and affective disorders,¹⁹⁶ and there is some epidemiological evidence relating autism to familial history of affective disorder.¹⁹⁷

If the cognitive profile in siblings is, as it seems, reflective of that in autism, then the same may be true at the levels of neuroanatomy, neurophysiology, and neurochemistry. Studies of first-degree relatives at these levels of analysis can expose primary factors closer to the roots of autistic brain development, unobscured by so many of the developmental sequelae that may overshadow or mask such factors in autism probands. In particular, there is a wealth of electrophysiological and morphometric findings in autism whose value would be greatly augmented if the same experiments and measures were applied in autism relatives, and the results compared. Do relatives manifest to any degree the anatomically overgeneralised activation found in autism probands during attentional tasks? Is focused spatial attention associated with abnormally modulated mid-latency visual evoked potentials as it is in autism probands? Are there any changes in the amplitude or latency of frontal negativities, or in the late positive component? Do relatives show any abnormality in cerebellar volume, or in cross-sectional area of the corpus

callosum? What about head circumference and early overgrowth of the frontal lobes? Many of these comparative questions can be answered quite easily, and should be addressed. Where differences exist, they may be subtle, and large groups of subjects may be required in order to achieve sufficient statistical power. As autism susceptibility genes begin to be identified, these nonautistic relatives will be of the utmost value in defining the behavioural and physiological phenotypes with which single susceptibility factors are associated.

The potential for large-scale secondary dysfunctions to mask more primary abnormalities has implications for studies within autism probands, too. A great deal of research attention has been devoted to autism's most apparent and most debilitating symptoms, those that make up the diagnostic triad of impaired social interaction, impaired communication, and restricted and repetitive interests and behaviours. Even physiological studies have addressed complex social capacities such as theory-of-mind²⁷ and emotion perception.²⁴ Observations at all levels of behavioural and physiological complexity are useful in reverse-engineering autistic development. However, in concentrating exclusively on the most diagnostic features of autism, such work may be overlooking cognitive and perceptual features at low levels of processing that are closer to autism's core dysfunction. There is a great need for further exploration of the neurophysiology associated with low-level perceptual abnormalities. It is quite remarkable and difficult to fathom that we currently have more functional imaging data about how the autistic brain processes a face or a theory of mind than we do about the way it processes, say, location, colour, orientation, or spatial frequency; at what level of processing do the perceptual and cognitive abnormalities begin? It is also important to recognise that absence of behavioural performance or functional activation does not necessarily imply incapacity of the corresponding brain subsystems. Rather, an apparent lack may be due to failure to engage an intact capacity. The proper stimuli or experimental paradigm can bring out such hidden abilities.

The finding of early brain overgrowth illustrates the importance of looking for primary abnormalities at the youngest possible ages, before all of the secondary changes have occurred. Although autism currently cannot be decisively diagnosed until the age of 5 years, its sibling recurrence risk of 4.5% opens the possibility of conducting the study in advance of the diagnosis. After the collection of data from all at-risk siblings, observations of siblings who do not meet full criteria at age 5 can be excluded from the autism sample. These observations of siblings who turn out not to have autism are not wasted, since, as noted previously, the sibling group is an informative contrast both to the autism group and to unrelated control subjects.

In addition to these more traditional, cognitively based elements of behaviour, attention must be paid

to even lower-level aspects of the phenotype. Parent reports are rife with anecdotal observations of low-level dysfunctions. Motor abnormalities, in particular, may be one of autism's earliest signs, appearing within the first year of life.¹⁹⁸ Abnormal gait is common in autism,¹⁹⁹ and motor clumsiness seems particularly prominent in Asperger syndrome.²⁰⁰ Other oft-reported abnormalities (e.g. gastrointestinal problems, blink rate, pupillary dilation), and the unproven interventions that have been designed around some of them, may yet contain a kernel of truth and should be subjected to controlled study.

A synthetic approach

Most experimental observations of autism yield correlations rather than definite causal relationships, and these correlations often exist in a vacuum: it is possible to implicate a chromosomal locus without knowing what genes it contains, a gene without knowing the function of its protein product, a protein without knowing its physiologic effects, and so forth. Connecting the many stages from genetics and biochemistry to brain structure and function and behaviour demands studies that bridge these levels of analysis. Postmortem studies and *in vivo* MRS studies aimed at elucidating the neuronal and molecular bases of early brain growth abnormalities in cerebellar and cerebral white matter and cerebral grey matter are needed. Studies can and should be designed to demonstrate explicitly relationships between such postmortem microscopic findings and *in vivo* MRI-based macroscopic effects. Also, detailed knowledge of brain growth defects may help guide the effort to create more developmentally realistic animal models of the disorder. Techniques such as MRI morphometry and event-related potentials make it possible to associate specific sites of brain abnormality with specific types of neurobehavioural deficits. Event-related potentials and other brain-behaviour correlation studies have elucidated relationships between anatomical sites of abnormality and deficits in visual selective attention, shifting attention, motor activation, motor learning, visuospatial exploration, and orienting attention. An important hypothesis for future research is that the age of onset, rate, and duration of aberrant brain growth are related to the severity and age of onset of autistic behaviours.

Like the individuals whom it seeks to understand, the field of autism research often falls victim to a sort of weak central coherence. Its challenge is to unify a complex set of local observations and details into coherent explanations of the autistic syndrome. Isolation of specific endophenotypes and examination of contributing genes will aid in uncovering the neurobiological roots of autism's core dysfunctions, while targeting low-level processes and examining early stages of development will highlight the steps through which those core dysfunctions unfold into autism's complex behavioural syndrome.

References

- 1 Frith U. *Autism: Explaining the Enigma*. Blackwell: Oxford, 1989.
- 2 Ozonoff S, Pennington B, Rogers SJ. Executive function deficits in high-functioning autistic individuals: relationship to theory of mind. *J Child Psychol Psychiatry* 1991; **32**: 1081–1105.
- 3 Baron-Cohen S, Leslie AM, Frith U. Does the autistic child have a 'theory of mind'? *Cognition* 1985; **21**: 37–46.
- 4 Baron-Cohen S. The extreme male brain theory of autism. *Trends Cogn Sci* 2002; **6**: 248–254.
- 5 Hashimoto T, Tayama M, Murakawa K, Yoshimoto T, Miyazaki M, Harada M *et al*. Development of the brainstem and cerebellum in autistic patients. *J Autism Devel Disord* 1995; **25**: 1–18.
- 6 Aylward EH, Minshew NJ, Goldstein G, Honeycutt NA, Augustine AM, Yates KO *et al*. MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults. *Neurology* 1999; **53**: 2145–2150.
- 7 Courchesne E, Karns C, Davis HR, Ziccardi R, Carper RA, Tigue ZD *et al*. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. *Neurology* 2001; **57**: 245–254.
- 8 Sparks BF, Friedman SD, Shaw DW, Aylward EH, Echelard D, Artru AA *et al*. Brain structural abnormalities in young children with autism spectrum disorder. *Neurology* 2002; **59**: 184–192.
- 9 Aylward EH, Minshew NJ, Field K, Sparks BF, Singh N. Effects of age on brain volume and head circumference in autism. *Neurology* 2002; **59**: 175–183.
- 10 Johnson MH, Halit H, Grice SJ, Karmiloff-Smith A. Neuroimaging of typical and atypical development: a perspective from multiple levels of analysis. *Dev Psychopathol* 2002; **14**: 521–536.
- 11 Rubia K. The dynamic approach to neurodevelopmental psychiatric disorders: use of fMRI combined with neuropsychology to elucidate the dynamics of psychiatric disorders, exemplified in ADHD and schizophrenia. *Behav Brain Res* 2002; **130**: 47–56.
- 12 Courchesne E, Chisum H, Townsend J. Neural activity-dependent brain changes in development: implications for psychopathology. *Dev Psychopathol* 1994; **6**: 697–722.
- 13 Akshoomoff N, Pierce K, Courchesne E. The neurobiological basis of autism from a developmental perspective. *Dev Psychopathol* 2002; **14**: 613–634.
- 14 Folstein SE, Rosen-Sheidley B. Genetics of autism: complex aetiology for a heterogeneous disorder. *Nat Rev Genet* 2001; **2**: 943–955.
- 15 Ballaban-Gil K, Tuchman R. Epilepsy and epileptiform EEG: association with autism and language disorders. *Ment Retard Dev Disabil Res* 2000; **6**: 300–308.
- 16 Bauman ML, Kemper TL. Neuroanatomic observations of the brain in autism. In: Bauman ML, Kemper TL (eds). *The Neurobiology of Autism*. Johns Hopkins University Press: Baltimore, MD, 1994 pp. 119–145.
- 17 Raymond G, Bauman M, Kemper T. Hippocampus in autism: a Golgi analysis. *Acta Neuropathol* 1996; **91**: 117–119.
- 18 Casanova MF, Buxhoeveden DP, Switala AE, Roy E. Minicolumnar pathology in autism. *Neurology* 2002; **58**: 428–432.
- 19 Cohen I. An artificial neural network analogue of learning in autism. *Biol Psychiatry* 1994; **36**: 5–20.
- 20 Belmonte MK, Yurgelun-Todd DA. Functional anatomy of impaired selective attention and compensatory processing in autism. *Cogn Brain Res* 2003; **17**: 651–664.
- 21 Tordjman S, Anderson GM, McBride PA, Hertzog ME, Snow ME, Hall LM *et al*. Plasma β -endorphin, adrenocorticotropin hormone, and cortisol in autism. *J Child Psychol Psychiatry* 1997; **38**: 705–715.
- 22 Hirstein W, Iversen P, Ramachandran VS. Autonomic responses of autistic children to people and objects. *Proc R Soc Lond B* 2001; **268**: 1883–1888.
- 23 Ring HA, Baron-Cohen S, Wheelwright S, Williams SCR, Brammer MJ, Andrew C *et al*. Cerebral correlates of preserved cognitive skills in autism. *Brain* 1999; **122**: 1305–1315.
- 24 Critchley HD, Daly EM, Bullmore ET, Williams SCR, Van Amelsvoort T, Robertson DM *et al*. The functional neuroanatomy of social behaviour: changes in cerebral blood flow when people with autistic disorder process facial expressions. *Brain* 2000; **123**: 2203–2212.
- 25 Schultz RT, Gauthier I, Klin A, Fulbright RK, Anderson AW, Volkmar F *et al*. Abnormal ventral temporal cortical activity during face discrimination among individuals with autism and Asperger syndrome. *Arch Gen Psychiatry* 2000; **57**: 331–340.
- 26 Pierce K, Müller R-A, Ambrose J, Allen G, Courchesne E. Face processing occurs outside the fusiform 'face area' in autism: evidence from functional MRI. *Brain* 2001; **124**: 2059–2073.
- 27 Baron-Cohen S, Ring HA, Wheelwright S, Bullmore ET, Brammer MJ, Simmons A *et al*. Social intelligence in the normal and autistic brain: an fMRI study. *Eur J Neurosci* 1999; **11**: 1891–1898.
- 28 Castelli F, Frith C, Happé F, Frith U. Autism, Asperger syndrome and brain mechanisms for the attribution of mental states to animated shapes. *Brain* 2002; **125**: 1839–1849.
- 29 Townsend J, Courchesne E. Parietal damage and narrow 'spotlight' spatial attention. *J Cogn Neurosci* 1994; **6**: 220–232.
- 30 Belmonte MK. Abnormal attention in autism shown by steady-state visual evoked potentials. *Autism* 2000; **4**: 269–285.
- 31 Kemner C, Verbaten MN, Cuperus JM, Camfferman G, van Engeland H. Visual and somatosensory event-related brain potentials in autistic children and three different control groups. *EEG Clin Neurophysiol* 1994; **92**: 225–237.
- 32 Kemner C, Verbaten MN, Cuperus JM, Camfferman G, van Engeland H. Auditory event-related brain potentials in autistic children and three different control groups. *Biol Psychiatry* 1995; **38**: 150–165.
- 33 Burack JA, Enns JT, Stauder JEA, Mottron L, Randolph B. Attention and autism: behavioral and electrophysiological evidence. In: Cohen DJ, Volkmar FR (eds). *Handbook of Autism and Pervasive Developmental Disorders*, 2nd edn. Wiley: New York, 1997 pp 226–247.
- 34 Courchesne R, Lincoln AJ *et al*. Impairment in shifting attention in autistic and cerebellar patients. *Behav Neurosci* 1994; **108**: 848–865.
- 35 Townsend J, Courchesne E, Covington J, Westerfield M, Harris NS, Lyden P *et al*. Spatial attention deficits in patients with acquired or developmental cerebellar abnormality. *J Neurosci* 1999; **19**: 5632–5643.
- 36 Courchesne E, Townsend J, Akshoomoff N, Yeung-Courchesne R, Lincoln AJ, Press G *et al*. A new finding: impairment in shifting attention in autistic and cerebellar patients. In: Broman SH, Grafman J (eds). *Atypical Cognitive Deficits in Developmental Disorders: Implications for Brain Function*. Lawrence Erlbaum: Hillsdale, NJ, 1994 pp 101–137.
- 37 Courchesne E, Lincoln AJ, Yeung-Courchesne R, Elmasian R, Grillon C. Pathophysiological findings in nonretarded autism and receptive developmental language disorder. *J Autism Dev Disord* 1989; **19**: 1–17.
- 38 Townsend J, Westerfield M, Leaver E, Makeig S, Jung T, Pierce K *et al*. Event-related brain response abnormalities in autism: evidence for impaired cerebello-frontal spatial attention networks. *Cogn Brain Res* 2001; **11**: 127–145.
- 39 Müller R-A, Kleinhans N, Kemmotsu N, Pierce K, Courchesne E. Abnormal variability and distribution of functional maps in autism: an fMRI study of visuomotor learning. *Am J Psychiatry* 2003; **160**: 1847–1862.
- 40 Shah A, Frith U. An islet of ability in autistic children: a research note. *J Child Psychol Psychiatry* 1983; **24**: 613–620.
- 41 Shah A, Frith U. Why do autistic individuals show superior performance on the block design task? *J Child Psychol Psychiatry* 1993; **34**: 1351–1364.
- 42 Whitehouse D, Harris JC. Hyperlexia in infantile autism. *J Autism Dev Disord* 1984; **14**: 281–289.
- 43 Boucher J, Lewis V. Unfamiliar face recognition in relatively able autistic children. *J Child Psychol Psychiatry* 1992; **33**: 843–859.
- 44 Klin A, Sparrow SS, de Bildt A, Cicchetti DV, Cohen DJ, Volkmar FR. A normed study of face recognition in autism and related disorders. *J Autism Dev Disord* 1999; **29**: 499–508.
- 45 Hobson RP, Ouston J, Lee A. What's in a face? *The case of autism*. *Br J Psychol* 1988; **79**: 441–453.
- 46 Tantam D, Monaghan L, Nicholson H, Stirling J. Autistic children's ability to interpret faces: a research note. *J Child Psychol Psychiatry* 1989; **30**: 623–630.

- 47 Toichi M, Kamio Y. Long-term memory and levels-of-processing in autism. *Neuropsychologia* 2002; **40**: 964–969.
- 48 Plaisted KG, Swettenham J, Rees L. Children with autism show local precedence in a divided attention task and global precedence in a selective attention task. *J Child Psychol Psychiatry* 1999; **40**: 733–742.
- 49 Plaisted KC, Saksida L, Alcántara J, Weisblatt E. Towards an understanding of the mechanisms of weak central coherence effects: experiments in visual configural learning and auditory perception. *Phil Trans R Soc Lond B* 2003; **358**: 375–386.
- 50 Mottron L, Burack JA. Enhanced perceptual functioning in the development of autism. In: Burack JA, Charman T, Yirmiya N, Zelazo PR (eds). *The Development of Autism: Perspectives from Theory and Research*. Lawrence Erlbaum Associates: Mahwah, NJ, 2001.
- 51 Frith U, Happé F. Autism: beyond 'theory of mind'. *Cognition* 1994; **50**: 115–132.
- 52 Russell J, Saltmarsh R, Hill E. What do executive factors contribute to the failure on false belief tasks by children with autism? *J Child Psychol Psychiatry* 1999; **40**: 859–868.
- 53 Klin A, Volkmar FR, Sparrow SS. Autistic social dysfunction: some limitations of the theory of mind hypothesis. *J Child Psychol Psychiatry* 1992; **33**: 861–876.
- 54 Rogers SJ, Pennington BF. A theoretical approach to the deficits in infantile autism. *Dev Psychopathol* 1991; **3**: 137–162.
- 55 Frith U. Mind blindness and the brain in autism. *Neuron* 2001; **32**: 969–979.
- 56 Courchesne E. Abnormal early brain development in autism. *Mol Psychiatry* 2002; **7**: S21–23.
- 57 Courchesne E, Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. *JAMA* 2003; **290**: 337–344.
- 58 Herbert MR, Ziegler DA, Makris N, Filipek PA, Kemper TL, Normandin JJ et al. Localization of white matter volume increase in autism and developmental language disorder. *Ann Neurol* 2004; **55**. (in press).
- 59 Carper RA, Moses P, Tighe ZD, Courchesne E. Cerebral lobes in autism: early hyperplasia and abnormal age effects. *NeuroImage* 2002; **16**: 1038–1051.
- 60 Yakovlev PI, Lecours A-R. The myelogenetic cycles of regional maturation of the brain. In: Minkowski A (ed). *Regional Development of the Brain in Early Life*. Blackwell: Oxford, 1967 pp 3–65.
- 61 Belmonte MK, Egaas B, Townsend J, Courchesne E. NMR intensity of corpus callosum differs with age but not with diagnosis of autism. *Neuroreport* 1995; **6**: 1253–1256.
- 62 Powell EM, Campbell DB, Stanwood GD, Davis C, Noebels JL, Levitt P. Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. *J Neurosci* 2003; **23**: 622–631.
- 63 Jorde L, Hasstedt S, Ritvo E, Mason-Brothers A, Freeman B, Pingree C et al. Complex segregation analysis of autism. *Am J Hum Genet* 1991; **49**: 932–938.
- 64 Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. *JAMA* 2001; **285**: 3093–3099.
- 65 Pickles A, Bolton P, Macdonald H, Bailey A, Le Couteur A, Sim CH et al. Latent-class analysis of recurrence risks for complex phenotypes with selection and measurement error: a twin and family history study of autism. *Am J Hum Genet* 1995; **57**: 717–726.
- 66 Risch N, Spiker D, Lotspeich L, Nouri N, Hinds D, Hallmayer J et al. A genomic screen of autism: evidence for a multilocus etiology. *Am J Hum Genet* 1999; **65**: 493–507.
- 67 Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? *Am J Hum Genet* 2001; **69**: 124–137.
- 68 Lauritsen M, Ewald H. The genetics of autism. *Acta Psychiatr Scand* 2001; **103**: 411–427.
- 69 Lamb JA, Parr JR, Bailey AJ, Monaco AP. Autism: in search of susceptibility genes. *Neuromol Med* 2002; **2**: 11–28.
- 70 Cook Jr EH. Genetics of autism. In: Cooper D (ed). *Nature Encyclopedia of the Human Genome*. Nature Publishing Group: London, 2003.
- 71 Geschwind DH, Sowsinski J, Lord C, Iversen P, Shestack J, Jones P et al. The autism genetic resource exchange: a resource for the study of autism and related neuropsychiatric conditions. *Am J Hum Genet* 2001; **69**: 463–466.
- 72 Jamain S, Quach H, Betancur C, Råstam M, Colineaux C, Gillberg IC et al. Paris Autism Research International Sibpair Study. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. *Nat Genet* 2003; **34**: 27–29.
- 73 Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet* 1999; **23**: 185–188.
- 74 Carney RM, Wolpert CM, Ravan SA, Shahbazian M, Ashley-Koch A, Cuccaro ML et al. Identification of MeCP2 mutations in a series of females with autistic disorder. *Pediatr Neurol* 2003; **28**: 205–211.
- 75 Bailey Jr DB, Hatton DD, Skinner M, Mesibov G. Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome. *J Autism Dev Disord* 2001; **31**: 165–174.
- 76 Wassink TH, Piven J, Patil SR. Chromosomal abnormalities in a clinic sample of individuals with autistic disorder. *Psychiatr Genet* 2001; **11**: 57–63.
- 77 Cohen, IL, Vietze PM, Sudhalter V, Jenkins EC, Brown WT. Effects of age and communication level on eye contact in fragile X males and non-fragile X autistic males. *Am J Med Genet* 1991; **38**: 498–502.
- 78 Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT et al. Absence of expression of the FMR-1 gene in fragile X syndrome. *Cell* 1991; **23**: 817–822.
- 79 Ashley Jr CT, Wilkinson KD, Reines D, Warren ST. FMR1 protein: conserved RNP family domains and selective RNA binding. *Science* 1993; **262**: 563–566.
- 80 Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu L et al. RNA cargoes associating with FMRP reveal deficits in cellular functioning in FMR1 null mice. *Neuron* 2003; **37**: 417–431.
- 81 Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K et al. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. *Proc Natl Acad Sci USA* 1997; **94**: 5395–5400.
- 82 Greenough WT, Klintsova AY, Irwin SA, Galvez R, Bates KE, Weiler IJ. Synaptic regulation of protein synthesis and the fragile X protein. *Proc Natl Acad Sci USA* 2001; **98**: 7101–7106.
- 83 Irwin SA, Swain RA, Christmon CA, Chakravarti A, Weiler IJ, Greenough WT. Evidence for altered fragile-X mental retardation protein expression in response to behavioral stimulation. *Neurobiol Learn Mem* 2000; **73**: 87–93.
- 84 Todd PK, Mack KJ. Sensory stimulation increases cortical expression of the fragile X mental retardation protein *in vivo*. *Mol Brain Res* 2000; **80**: 17–25.
- 85 Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA, Weiler IJ et al. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. *Proc Natl Acad Sci USA* 1997; **94**: 5401–5404.
- 86 Galvez R, Gopal AR, Greenough WT. Somatosensory cortical barrel dendritic abnormalities in a mouse model of the fragile X mental retardation syndrome. *Brain Res* 2003; **971**: 83–89.
- 87 Irwin SA, Patel B, Idupulapati M, Harris JB, Crisostomo RA, Larsen BP et al. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. *Am J Med Genet* 2001; **98**: 161–167.
- 88 Jiang YH, Tsai TF, Bressler J, Beaudet AL. Imprinting in Angelman and Prader-Willi syndromes. *Curr Opin Genet Dev* 1998; **8**: 334–342.
- 89 Beaudet AL. Is medical genetics neglecting epigenetics? *Genet Med* 2002; **4**: 399–402.
- 90 Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. *Science* 2001; **293**: 1089–1093.
- 91 Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. *Neuron* 1998; **21**: 799–811.

- 92 Yu Y, Bradley A. Engineering chromosomal rearrangements in mice. *Nat Rev Genet* 2001; **2**: 780–790.
- 93 DeFelipe J, Hendry SH, Hashikawa T, Molinari M, Jones EG. A microcolumnar structure of monkey cerebral cortex revealed by immunocytochemical studies of double bouquet cell axons. *Neuroscience* 1990; **23**: 622–631.
- 94 Peters A, Sethares C. The organization of double bouquet cells in monkey striate cortex. *J Neurocytol* 1997; **26**: 779–797.
- 95 Anderson S, Qiu M, Bulfone A, Eisenstat D, Meneses JJ, Pedersen RA et al. Mutations of the homeobox genes *Dlx-1* and *Dlx-2* disrupt the striatal subventricular zone and differentiation of late-born striatal cells. *Neuron* 1997; **19**: 27–37.
- 96 Blatt GJ, Fitzgerald CM, Guptill JT, Booker AB, Kemper TL, Bauman ML. Density and distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. *J Autism Dev Disord* 2001; **31**: 537–543.
- 97 Rolf LH, Haarmann FY, Grotemeyer KH, Kehrer H. Serotonin and amino acid content in platelets of autistic children. *Acta Psychiatr Scand* 1993; **87**: 312–316.
- 98 Rubenstein JLR, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. *Genes Brain Behav* 2003; **2**: 255–267.
- 99 Hensch TK, Fagiolini M, Mataga N, Stryker MP, Baekkeskov S, Kash SF. Local GABA circuit control of experience-dependent plasticity in the developing visual cortex. *Science* 1998; **282**: 1504–1508.
- 100 Marin O, Rubenstein JLR. A long, remarkable journey: cellular and molecular mechanisms of tangential migration in the telencephalon. *Nat Neurosci Rev* 2001; **2**: 780–790.
- 101 IMGSAC. A genomewide screen for autism: strong evidence for linkage to chromosomes 2q, 7q, and 16p. *Am J Hum Genet* 2001; **69**: 570–581.
- 102 Stühmer T, Anderson SA, Ekker M, Rubenstein JLR. Ectopic expression of the *Dlx* genes induces glutamic acid decarboxylase and *Dlx* expression. *Development* 2002; **129**: 245–252.
- 103 Stühmer T, Puelles L, Ekker M, Rubenstein JLR. Expression from a *Dlx* gene enhancer marks adult mouse cortical GABAergic neurons. *Cereb Cortex* 2002; **12**: 75–85.
- 104 Long JE, Garel S, Depew M, Tobet S, Rubenstein JLR. *DLX5* regulates development of peripheral and central components of the olfactory system. *J Neurosci* 2003; **23**: 568–578.
- 105 Alcantara S, Ruiz M, D'Arcangelo G, Ezan F, de Lecea L, Curran T et al. Regional and cellular patterns of reelin mRNA expression in the forebrain of the developing and adult mouse. *J Neurosci* 1998; **18**: 7779–7799.
- 106 Laurie DJ, Wisden W, Seeburg PH. The distribution of thirteen GABA_A receptor subunit mRNAs in the brain. III. Embryonic and postnatal development. *J Neurosci* 1992; **12**: 4151–4172.
- 107 DeLorey TM, Handforth A, Anagnostaras SG, Homanics GE, Minassian BA, Asatourian A et al. Mice lacking the β_3 subunit of the GABA_A receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome. *J Neurosci* 1998; **18**: 8505–8514.
- 108 Homanics GE, DeLorey TM, Firestone LL, Quinlan JJ, Handforth A, Harrison NL et al. Mice devoid of γ -aminobutyrate type A receptor β_3 subunit have epilepsy, cleft palate, and hypersensitive behavior. *Proc Natl Acad Sci USA* 1997; **94**: 4143–4148.
- 109 Ugarte SD, Homanics GE, Firestone LL, Hammond DL. Sensory thresholds and the antinociceptive effects of GABA receptor agonists in mice lacking the β_3 subunit of the GABA_A receptor. *Neuroscience* 2000; **95**: 795–806.
- 110 Wisor JP, DeLorey TM, Homanics GE, Edgar DM. Sleep states and sleep electroencephalographic spectral power in mice lacking the β_3 subunit of the GABA_A receptor. *Brain Res* 2002; **955**: 221–228.
- 111 Mirza NR, Stolerman IP. The role of nicotinic and muscarinic acetylcholine receptors in attention. *Psychopharmacology* 2000; **148**: 243–250.
- 112 Kimura F. Cholinergic modulation of cortical function: a hypothetical role in shifting the dynamics in cortical network. *Neurosci Res* 2000; **38**: 19–26.
- 113 Marubio LM, del Mar Arroyo- Jimenez M, Cordero-Erausquin M, Lena C, Le Novere N, de Kerchove d'Exaerde A et al. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. *Nature* 1999; **398**: 805–810.
- 114 Picciotto MR, Brunzell DH, Caldarone BJ. Effect of nicotine and nicotinic receptors on anxiety and depression. *Neuroreport* 2002; **13**: 1097–1106.
- 115 Court JA, Martin-Ruiz C, Graham A, Perry E. Nicotinic receptors in human brain: topography and pathology. *J Chem Neuroanat* 2000; **20**: 281–298.
- 116 Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M et al. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. *Eur J Pharmacol* 2000; **393**: 215–222.
- 117 Lee M, Martin-Ruiz C, Graham A, Court J, Jaros E, Perry R et al. Nicotinic receptor abnormalities in the cerebellar cortex in autism. *Brain* 2002; **125**: 1483–1495.
- 118 Alkondon M, Albuquerque EX. Nicotinic acetylcholine receptor α_7 and $\alpha_4\beta_2$ subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. *J Neurophysiol* 2001; **86**: 3043–3055.
- 119 Hohmann CF, Berger-Sweeney J. Cholinergic regulation of cortical development and plasticity. New twists to an old story. *Perspect Dev Neurobiol* 1998; **5**: 401–425.
- 120 Ward NL, Hagg T. BDNF is needed for postnatal maturation of basal forebrain and neostriatum cholinergic neurons *in vivo*. *Exp Neurol* 2000; **162**: 297–310.
- 121 Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. *J Child Adolesc Psychopharmacol* 2002; **12**: 237–241.
- 122 Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. *J Pediatr* 1961; **58**: 315–320.
- 123 Whitaker-Azmitia PM. Serotonin and brain development: role in human developmental diseases. *Brain Res Bull* 2001; **56**: 479–485.
- 124 Lucki I. The spectrum of behaviors influenced by serotonin. *Biol Psychiatry* 1998; **44**: 151–162.
- 125 Posey DJ, McDougle CJ. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. *Harvard Rev Psychiatry* 2000; **8**: 45–63.
- 126 Cook Jr EH, Leventhal BL. The serotonin system in autism. *Curr Opin Pediatr* 1996; **8**: 348–354.
- 127 Anderson GM, Gutknecht L, Cohen DJ, Brailly-Tabard S, Cohen JH, Ferrari P et al. Serotonin transporter promoter variants in autism: functional effects and relationship to platelet hyperserotonemia. *Mol Psychiatry* 2002; **7**: 831–836.
- 128 Veenstra-VanderWeele J, Anderson GM, Cook Jr EH. Pharmacogenetics and the serotonin system: initial studies and future directions. *Eur J Pharmacol* 2000; **410**: 165–181.
- 129 Kim SJ, Cox N, Courchesne R, Lord C, Corsello C, Akshoomoff N et al. Transmission disequilibrium mapping at the serotonin transporter gene (*SLC6A4*) region in autistic disorder. *Mol Psychiatry* 2002; **7**: 278–288.
- 130 Tordjman S, Gutnecht L, Carlier M, Spitz E, Antoine C, Slama F et al. Role of the serotonin transporter in the behavioral expression of autism. *Mol Psychiatry* 2001; **6**: 434–439.
- 131 McCauley JL, Olson LM, Dowd M, Amin T, Steele A, Blakely RD et al. Linkage and association analysis at the serotonin transporter (*SLC6A4*) locus in a rigid-compulsive subset of autism. *Am J Med Genet* 2004; doi:10.1002/ajmg.b.20151.
- 132 Smith DW, Lemli L, Opitz JM. A newly recognized syndrome of multiple congenital anomalies. *J Pediatr* 1964; **64**: 210–217.
- 133 Kelley RI, Hennekam RCH. Smith-Lemli-Opitz Syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D. (eds) *The Metabolic and Molecular Basis of Inherited Disease*, 8th edn. McGraw-Hill: New York, 2000.
- 134 Tint GS, Irons M, Elias ER, Batta AK, Frieden R, Chen TS et al. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. *N Engl J Med* 1994; **330**: 107–113.
- 135 Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview—Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. *J Autism Dev Disord* 1994; **24**: 659–685.

- 136 Tierney E, Nwokoro NA, Porter FD, Freund LS, Ghuman JK, Kelly RI. The behavior phenotype in the RSH/Smith-Lemli-Opitz syndrome. *Am J Med Genet* 2001; **98**: 191–200.
- 137 Warren RP, Odell JD, Warren WL, Burger RA, Maciulis A, Daniels WW et al. Strong association of the third hypervariable region of HLA-DR β_1 with autism. *J Neuroimmunol* 1996; **67**: 97–102.
- 138 Rogers T, Kalaydjieva L, Hallmayer J, Peterson PB, Nicholas P, Pingree C et al. Exclusion of linkage to the HLA region in ninety multiplex sibships with autism. *J Autism Dev Disord* 1999; **29**: 195–201.
- 139 Warren RP, Burger RA, Odell D, Torres AR, Warren WL. Decreased plasma concentrations of the C4B complement protein in autism. *Arch Pediatr Adolesc Med* 1994; **148**: 180–183.
- 140 Krause I, He X-S, Gershwin ME, Shoenfeld Y. Immune factors in autism: a critical review. *J Autism Devel Disord* 2002; **32**: 337–345.
- 141 Connolly AM, Chez MG, Pestronk A, Arnold ST, Mehta S, Deuel RK. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurological disorders. *J Pediatrics* 1999; **134**: 607–613.
- 142 Denney DR, Frei BW, Gaffney GR. Lymphocyte subsets and interleukin-2 receptors in autistic children. *J Autism Dev Disord* 1996; **26**: 87–97.
- 143 Warren RP, Foster A, Margaretten NC. Reduced natural killer cell activity in autism. *J Amer Acad Child Adolesc Psychiatry* 1987; **26**: 333–335.
- 144 Gupta S, Aggarwal S, Rathanravan B, Lee T. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. *J Neuroimmunol* 1998; **85**: 106–109.
- 145 Hugdahl K, Synnevag B, Satz P. Immune and autoimmune diseases in dyslexic children. *Neuropsychologia* 1990; **28**: 673–679.
- 146 Cardon LR, Smith SD, Fulker DW, Kimberling WJ, Pennington BF, DeFries JC. Quantitative trait locus for reading disability on chromosome 6. *Science* 1994; **266**: 276–279.
- 147 Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. *J Child Neurol* 1999; **14**: 388–394.
- 148 Young MR, Kut JL, Coogan MP, Wright MA, Young ME, Matthews J. Stimulation of splenic T-lymphocyte function by endogenous serotonin and by low-dose exogenous serotonin. *Immunology* 1993; **80**: 395–400.
- 149 Fatemi SH, Earle J, Kanodia R, Kist D, Emamian ES, Patterson PH et al. Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: implications for genesis of autism and schizophrenia. *Cell Mol Neurobiol* 2002; **22**: 25–33.
- 150 Shi L, Fatemi SH, Sidwell RW, Patterson PH. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. *J Neurosci* 2003; **23**: 297–302.
- 151 Patterson PH. Maternal infection: window on neuroimmune interactions in fetal brain development and mental illness. *Curr Opin Neurobiol* 2002; **12**: 115–118.
- 152 Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, Shatz CJ. Functional requirement for class I MHC in CNS development and plasticity. *Science* 2000; **290**: 2155–2159.
- 153 Dalton P, Deacon R, Blamire A, Pike M, McKinlay I, Stein J et al. Maternal neuronal antibodies associated with autism and a language disorder. *Ann Neurol* 2003; **53**: 533–537.
- 154 Corriveau RA, Huh GS, Shatz CJ. Regulation of class I MHC gene expression in the developing and mature CNS by neural activity. *Neuron* 1998; **21**: 505–520.
- 155 Boulanger LM, Huh GS, Shatz CJ. Neuronal plasticity and cellular immunity: shared molecular mechanisms. *Curr Opin Neurobiol* 2001; **11**: 568–578.
- 156 Machado CJ, Bachevalier J. Non-human primate models of childhood psychopathology: the promise and the limitations. *J Child Psychol Psychiatry* 2003; **44**: 64–87.
- 157 Geyer MA, Markou A. Animal models of psychiatric disorders. In: Bloom FE, Kupfer D (eds). *Psychopharmacology: The Fourth Generation of Progress*. Raven Press: New York, 1995 pp 787–798.
- 158 Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. *Neuropsychopharmacology* 2000; **23**: 223–239.
- 159 Graham F. The more or less startling effects of weak prestimulation. *Psychophysiology* 1975; **12**: 238–248.
- 160 Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. *Psychopharmacology* 2001; **156**: 234–258.
- 161 Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. *Psychopharmacology* 2001; **156**: 117–154.
- 162 Swerdlow NR, Geyer MA, Braff DL. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. *Psychopharmacology* 2001; **156**: 194–215.
- 163 Swerdlow NR, Braff DL, Taid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. *Arch Gen Psychiatry* 1994; **51**: 139–154.
- 164 Ornitz EM, Lane SJ, Sugiyama T, de Traversay J. Startle modulation studies in autism. *J Autism Dev Disord* 1993; **23**: 619–637.
- 165 McAlonan GM, Daly E, Kumari V, Critchley HD, van Amelsvoort T, Suckling J et al. Brain anatomy and sensorimotor gating in Asperger's syndrome. *Brain* 2002; **125**: 1594–1606.
- 166 Stevens S, Gruzelier J. Electrodermal activity to auditory stimuli in autistic, retarded, and normal children. *J Autism Dev Disord* 1984; **14**: 245–260.
- 167 van Engeland H. The electrodermal orienting response to auditory stimuli in autistic children, normal children, mentally retarded children, and child psychiatric patients. *J Autism Dev Disord* 1984; **14**: 261–279.
- 168 Belser RC, Sudhalter V. Arousal difficulties in males with fragile X syndrome: a preliminary report. *Dev Brain Dysfunct* 1995; **8**: 270–279.
- 169 Miller LJ, McIntosh DN, McGrath J, Shyu V, Lampe M, Taylor AK et al. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. *Am J Med Genet* 1999; **83**: 268–279.
- 170 Powell SB, Geyer MA. Developmental markers of psychiatric disorders as identified by sensorimotor gating. *Neurotoxic Res* 2002; **4**: 489–502.
- 171 Pletnikov MV, Rubin SA, Vasudevan K, Moran TH, Carbone KM. Developmental brain injury associated with abnormal play behavior in neonatally Borna disease virus-infected Lewis rats: a model of autism. *Behav Brain Res* 1999; **100**: 43–50.
- 172 Ingram JL, Peckham SM, Tisdale B, Rodier PM. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. *Neurotoxic Teratol* 2000; **22**: 319–324.
- 173 Caston J, Yon E, Mellier D, Godfrey HP, Delhaye-Bouchard N, Mariani J. An animal model of autism: behavioural studies in the GS guinea pig. *Eur J Neurosci* 1998; **10**: 2677–2684.
- 174 Kuwamura M, Morikawa T, Yamate J, Kato K, Kotani T, Sakuma S. Glial pathology in development of cerebellar dysplasia in the hereditary cerebellar vermis defect (cvd) rat. *Acta Neuropathol* 2000; **99**: 305–309.
- 175 Bobee S, Mariette E, Tremblay-Leveau H, Caston J. Effects of early midline cerebellar lesion on cognitive and emotional functions in the rat. *Behav Brain Res* 2000; **112**: 107–117.
- 176 Tueting P, Costa E, Dwivedi Y, Guidotti A, Impagnatiello F, Manev R et al. The phenotypic characteristics of heterozygous reeler mouse. *Neuroreport* 1999; **10**: 1329–1334.
- 177 Park C, Falls W, Finger JH, Longo-Guess CM, Ackerman SL. Deletion in *Catna2*, encoding α N-catenin, causes cerebellar and hippocampal lamination defects and impaired startle modulation. *Nat Genet* 2002; **31**: 279–284.
- 178 Chang EF, Merzenich MM. Environmental noise retards auditory cortical development. *Science* 2003; **300**: 498–502.
- 179 Pierce K, Courchesne E. Evidence for a cerebellar role in reduced exploration and stereotyped behavior in autism. *Biol Psychiatry* 2001; **49**: 655–664.
- 180 Lalonde R, Manseau M, Boetz MI. Exploration and habituation in Purkinje cell degeneration mutant mice. *Brain Res* 1989; **479**: 201–203.
- 181 Kamiguchi H, Hlavin ML, Lemmon V. Role of L1 in neural development: what the knockouts tell us. *Mol Cell Neurosci* 1998; **12**: 48–55.

- 182 Fransen E, D'Hooge R, Van Camp G, Verhoye M, Sijbers J, Reyniers E *et al*. L1 knockout mice show dilated ventricles, vermis hypoplasia and impaired exploration patterns. *Hum Mol Genet* 1998; **7**: 999–1009.
- 183 Leaton RN, Supple Jr WF. Medial cerebellum and long-term habituation of acoustic startle in rats. *Behav Neurosci* 1991; **105**: 804–816.
- 184 Silverman JM, Smith CJ, Schmeidler J, Hollander E, Lawlor BA, Fitzgerald M *et al*. Symptom domains in autism and related conditions: evidence for familiarity. *Am J Med Genet* 2002; **114**: 64–73.
- 185 Hughes C, Plumet MH, Leboyer M. Towards a cognitive phenotype for autism: increased prevalence of executive dysfunction and superior spatial span amongst siblings of children with autism. *J Child Psychol Psychiatry* 1999; **40**: 705–718.
- 186 Baron-Cohen S, Hammer J. Parents of children with Asperger syndrome: what is the cognitive phenotype? *J Cogn Neurosci* 1997; **9**: 548–554.
- 187 O'Riordan MA, Plaisted KG, Driver J, Baron-Cohen S. Superior visual search in autism. *J Exp Psychol Hum Percept Perform* 2001; **27**: 719–730.
- 188 Happ F, Briskman J, Frith U. Exploring the cognitive phenotype of autism: weak 'central coherence' in parents and siblings of children with autism: I. *Experimental tests*. *J Child Psychol Psychiatry* 2001; **42**: 299–307.
- 189 Folstein SE, Gilman SE, Landa R, Hein J, Santangelo SL, Piven J *et al*. Predictors of cognitive test patterns in autism families. *J Child Psychol Psychiatry* 1999; **40**: 1117–1128.
- 190 Hughes C, Leboyer M, Bouvard M. Executive function in parents of children with autism. *Psychol Med* 1997; **27**: 209–220.
- 191 Piven J, Palmer P, Landa R, Santangelo S, Jacobi D, Childress D. Personality and language characteristics in parents from multiple-incidence autism families. *Am J Med Genet* 1997; **74**: 398–411.
- 192 Fombonne E, Bolton P, Prior J, Jordan H, Rutter M. A family study of autism: cognitive patterns and levels in parents and siblings. *J Child Psychol Psychiatry* 1997; **38**: 667–683.
- 193 Piven J, Palmer P. Cognitive deficits in parents from multiple-incidence autism families. *J Child Psychol Psychiatry* 1994; **38**: 1011–1021.
- 194 Baron-Cohen S, Wheelwright S, Stott C, Bolton P, Goodyer I. Is there a link between engineering and autism? *Autism* 1997; **1**: 153–163.
- 195 Baron-Cohen S, Bolton P, Wheelwright S, Scahill V, Short L, Mead G *et al*. Autism occurs more often in families of physicists, engineers, and mathematicians. *Autism* 1998; **2**: 296–301.
- 196 Piven J, Gayle J, Chase GA, Fink B, Landa R, Wzorek MM *et al*. A family history study of neuropsychiatric disorders in the adult siblings of autistic individuals. *J Am Acad Child Adolesc Psychiatry* 1990; **29**: 177–183.
- 197 DeLong R, Nohria C. Psychiatric family history and neurological disease in autistic spectrum disorders. *Dev Med Child Neurol* 1994; **36**: 441–448.
- 198 Baranek GT. Autism during infancy: a retrospective video analysis of sensory-motor and social behaviors at 9–12 months of age. *J Autism Dev Disord* 1999; **29**: 213–224.
- 199 Hallett M, Lebedowska MK, Thomas SL, Stanhope SJ, Denckla MB, Rumsey J. Locomotion of autistic adults. *Arch Neurol* 1993; **50**: 1304–1308.
- 200 Smith IM. Motor functioning in Asperger's syndrome. In: Klin A, Volkmar FR, Sparrow SS (eds). *Asperger's Syndrome*. The Guildford Press: New York, 2000.